Download PDF
Semin Thromb Hemost 2002; 28(2): 139-148
DOI: 10.1055/s-2002-27816
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Comparison of Two von Willebrand Factor Collagen-Binding Assays with Different Binding Affinities for Low, Medium, and High Multimers of von Willebrand Factor

Brigitte M. Neugebauer, Christine Goy, Irmhild Budek, Rainer Seitz
  • Paul-Ehrlich-Institut, Langen, Germany
Further Information

Publication History

Publication Date:
03 May 2002 (online)

    Permissions and Reprints

ABSTRACT

The use of von Willebrand factor collagen-binding assay (vWF:CBA[*]) as an alternative method for the quantification of the physiological activity of vWF in plasma from patients with von Willebrand disease (vWD) and in blood clotting factor (F) VIII concentrates (FVIII/vWF concentrates) for the therapy of vWD is currently being discussed. We compared two vWF:CBAs that are distinctive with regard to the type and structure of collagen and the coating principle used. After analyzing samples of a plasma pool from normal donors, we received results that were in very good compliance with both methods. However, significantly different results (p ≤0.005) were obtained when FVIII/vWF concentrates were tested. In an attempt to elucidate these discrepancies, vWF multimers were separated by heparin affinity chromatography and analyzed by vWF antigen enzyme-linked immunosorbent assay (ELISA), ristocetin cofactor activity test, both vWF:CBAs, and a multimer analysis. From our data we conclude that the assay with pepsin-digested collagen (human, type III) that was covalently linked to preactivated microtiter plates (vWF:CBAPDC) revealed a higher affinity for low and medium vWF multimers, whereas the assay with collagen fibrils (equine, type I) that were adsorbed to microtiter plates (vWF:CBACF) predominantly bound high vWF multimers. Based on results reported by others, we assume that the discrepancies between both vWF:CBAs were not related to the type and species of collagen used. Taken together our results imply rather that fragmentation of collagen by pepsin digestion or subsequent covalent linkage to the microtiter plate, or both, increased the affinity for low and medium vWF multimers, whereas the fibrillar structure of collagen was required for the binding of high vWF multimers, which exhibit the highest physiological activity in primary hemostasis.

KEYWORDS

von Willebrand factor collagen-binding assay - human pepsin-digested collagen type III - equine collagen type I fibrils - von Willebrand disease - factor VIII concentrates

1 *The abbreviation vWF:CBA is also used for vWF-collagen binding activity.

REFERENCES

  • 1 Savage B, Saldivar E, Ruggeri Z M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.  Cell . 1996;  84 289-297
    CrossrefPubMedGoogle Scholar
  • 2 Ruggeri Z M, Dent J A, Saldivar E. Contribution of distinctive adhesions interactions to platelet aggregation in flowing blood.  Blood . 1999;  94 172-178
    PubMedGoogle Scholar
  • 3 Santoro S A. Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen.  Biochim Biophys Acta . 1983;  756 123-126
    PubMedGoogle Scholar
  • 4 Federici A B, Bader R, Pagani S. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size.  Br J Haematol . 1989;  73 93-99
    PubMedGoogle Scholar
  • 5 Mannucci P M, Lattuada A, Ruggeri Z M. Proteolysis of von Willebrand factor in therapeutic plasma concentrates.  Blood . 1994;  83 3018-3027
    PubMedGoogle Scholar
  • 6 Sixma J J, Sakariassen K S, Beeser-Visser N H. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition.  Blood . 1984;  63 128-139
    PubMedGoogle Scholar
  • 7 Sixma J J, Schiphorst M E, Verweij C L. Effects of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.  Eur J Biochem . 1991;  196 369-375
    CrossrefPubMedGoogle Scholar
  • 8 Mohri H, Yoshioka A, Zimmerman T S. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites.  J Biol Chem . 1989;  264 17361-17367
    PubMedGoogle Scholar
  • 9 Cruz M A, Handin R I, Wise R J. The interaction of the von Willebrand factor A1 domain with platelet glycoprotein Ib/IX.  J Biol Chem . 1993;  268 21238-21245
    PubMedGoogle Scholar
  • 10 Fischer B E, Kramer G, Mitterer A. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  Thromb Res . 1996;  84 55-66
    CrossrefPubMedGoogle Scholar
  • 11 Siekmann J, Turecek P L, Schwarz H P. The determination of von Willebrand factor activity by collagen binding assay.  Haemophilia . 1998;  4(Suppl 3) 15-24
    PubMedGoogle Scholar
  • 12 Brown J E, Bosak J O. An ELISA for the binding of von Willebrand antigen to collagen.  Thromb Res . 1986;  43 303-311
    CrossrefPubMedGoogle Scholar
  • 13 Thomas K B, Choong S C, Jessat U. Platelet von Willebrand factor-collagen binding activity and ristocetin cofactor activity: a comparison of methods able to differentiate von Willebrand disease types I and II (preliminary results). In: Scharrer I, Schramm W, eds. 24. Hämophilie Symposium Hamburg 1993, Berlin: Springer-Verlag 1994: 234-242
    Google Scholar
  • 14 Schneppenheim R, Plendl H, Budde U. Luminography-an alternative assay for the detection of von Willebrand factor multimers.  Thromb Haemost . 1988;  60 133-136
    PubMedGoogle Scholar
  • 15 Ramasamy I, Farrugia A, Tran E. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.  Biologicals . 1998;  26 155-166
    CrossrefPubMedGoogle Scholar
  • 16 Siekmann J, Turecek P L, Schwarz H P. The hemostatic potency of von Willebrand factor in FVIII/vWF concentrates is reflected by affinity to immobilized heparin.  Ann Hematol (Abst) . 1999;  78(Suppl I) A61
    PubMedGoogle Scholar
  • 17 Favoloro E J. Collagen binding assay for von Willebrand factor (vWF:CBA): detection of von Willebrand disease (vWD), and discrimination of vWD subtypes, depends on the collagen source.  Thromb Haemost . 2000;  83 127-135
    PubMedGoogle Scholar
  • 18 Savage B, Ginsberg M H, Ruggeri Z M. Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow.  Blood . 1999;  94 2704-2715
    PubMedGoogle Scholar
  • 19 Miller E J, Gay G. Collagen: an overview.  Methods Enzymol . 1982;  82 3-32
    PubMedGoogle Scholar
  • 20 Miyahara M, Hayashi K, Berger J. Formation of collagen fibrils by enzymatic cleavage of precursors of type I collagen in vitro.  J Biol Chem . 1984;  259 9891-9898
    PubMedGoogle Scholar
  • 21 Favaloro E J. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects.  Am J Clin Pathol . 2000;  114 608-618
    CrossrefPubMedGoogle Scholar

1 *The abbreviation vWF:CBA is also used for vWF-collagen binding activity.